ERBB2 and breast carcinoma: Furthermore, DESTINY-Breast15 (NCT05950945) is a phase III clinical trial aiming to comprehensively investigate the role of T-DXd in unresectable and/or metastatic HR-negative/positive breast cancer with HER2 low or HER2 immunohistochemistry (IHC) of 0.